PHILADELPHIA -- Although leukemia is one of the best studied cancers, the cause of some types is still poorly understoodNow, a newly found mutation in acute myeloid leukemia patients could account for half of the remaining cases of adult acute leukemia with an unknown origin"The molecular biology

read more>>

ROCKVILLE, MD -- EntreMed, Inc. (Nasdaq: ENMD), today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company’s lead oncology drug candidate, ENMD-2076, for the treatment of acute myeloid leukemia (AMLThe FDA accepted EntreMed’s a

read more>>

Montréal -- A large international research group led by Dr. Tarik Möröy, a researcher at the Institut de recherches cliniques de Montréal (IRCM), has discovered that a variant of the gene "Growth Factor Independence 1" (GFI1) predisposes humans to develop acute myeloid This

read more>>

Older patients with acute myeloid leukemia (AML) might benefit from a drug that reactivates genes that cancer cells turn off, according to research at Washington University School of Medicine in St. Louis and collaborating institutionsThe researchers say the findings support further investigation

read more>>

NEW YORK  -- A tumor's genetic profile is often useful when diagnosing and deciding on treatment for certain cancers, but inexplicably, genetically similar leukemias in different patients do not always respond well to the same therapyWeill Cornell Medical College researchers believe they may

read more>>

Xenomics, Inc. (Pink Sheets: XNOM), a developer of transrenal molecular diagnostics, announced today that a key Italian patent covering a unique diagnostic application with critical significance for patients with acute myeloid leukemia (AML) has issuedThe patent, entitled: “Nucleophosmin pro

read more>>

Researchers at the Program in Cellular and Molecular Medicine and the Immune Disease Institute at Children's Hospital Boston (PCMM/IDI) have found a link between a common mutation that can lead to cancer and a distant gene regulator that enhances its activityDiscovery of this relationship could le

read more>>

Children and adolescents who survive cancer have a significantly higher risk of developing heart disease as young adults, according to the largest study on this issue published on bmj.com todayThe findings show that young adult survivors of childhood cancer are at risk for a variety of cardiovascu

read more>>

EUREKA project E! 3172 NKSTIM has produced a new potential drug to stimulate cancer patients' own 'natural killer' cells to attack and eliminate cancer cells; currently undergoing clinical testing in patients with leukaemia or myelomaExisting knowledge of how transplanted bone marrow cells eradica

read more>>

CAMBRIDGE, Mass. -- Genzyme Corporation (Nasdaq: GENZ) announced today that a Phase 1/2 trial provided early clinical data suggesting that Mozobil® (plerixafor injection) in combination with chemotherapy may offer a therapeutic impact on leukemic cells protected in bone marrowThe investigation

read more>>